☰

Nandini Verma - Publications

Affiliations: 
Molecular Cell Biology Weizmann Institute of Science, Rehovot, Israel 
Tree Info Grants Similar researchers PubMed Report error

7 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Verma N, Vinik Y, Saroha A, Nair NU, Ruppin E, Mills G, Karn T, Dubey V, Khera L, Raj H, Maina F, Lev S. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Science Advances. 6. PMID 32937365 DOI: 10.1126/Sciadv.Aba8968  0.682
2020 Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM. HER family in cancer progression: From discovery to 2020 and beyond. Advances in Cancer Research. 147: 109-160. PMID 32593399 DOI: 10.1016/bs.acr.2020.04.001  0.392
2020 Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S. Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Research. 80: 362. PMID 31941679 DOI: 10.1158/0008-5472.CAN-19-3573  0.61
2018 Kedan A, Verma N, Saroha A, Shreberk-Shaked M, Müller AK, Nair NU, Lev S. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein. Cell Death & Disease. 9: 985. PMID 30250159 DOI: 10.1038/S41419-018-1005-Z  0.741
2018 Shin SY, Müller AK, Verma N, Lev S, Nguyen LK. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. Plos Computational Biology. 14: e1006192. PMID 29920512 DOI: 10.1371/Journal.Pcbi.1006192  0.724
2016 Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S. Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis. Cancer Research. PMID 27793840 DOI: 10.1158/0008-5472.Can-16-1797  0.633
2015 Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S. PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nature Communications. 6: 6064. PMID 25648557 DOI: 10.1038/Ncomms7064  0.686
Show low-probability matches.